Ellington Management Group’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-16,800
| Closed | -$128K | – | 389 |
|
|
2018
Q3 | $128K | Buy |
+16,800
| New | +$128K | 0.03% | 464 |
|
|
2017
Q3 | – | Sell |
-34,600
| Closed | -$192K | – | 627 |
|
|
2017
Q2 | $192K | Buy |
+34,600
| New | +$192K | 0.03% | 535 |
|
|
2017
Q1 | – | Sell |
-17,400
| Closed | -$110K | – | 681 |
|
|
2016
Q4 | $110K | Buy |
+17,400
| New | +$110K | 0.02% | 483 |
|
|
2015
Q3 | – | Sell |
-11,719
| Closed | -$175K | – | 709 |
|
|
2015
Q2 | $175K | Buy |
+11,719
| New | +$175K | 0.04% | 610 |
|
|
2015
Q1 | – | Sell |
-18,300
| Closed | -$223K | – | 677 |
|
|
2014
Q4 | $223K | Buy |
+18,300
| New | +$223K | 0.07% | 416 |
|
|
2014
Q2 | – | Sell |
-32,500
| Closed | -$344K | – | 451 |
|
|
2014
Q1 | $344K | Buy |
+32,500
| New | +$344K | 0.1% | 313 |
|